Project Grant R01CA140371

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,042,976 to Indiana University Indianapolis to adapt flow cytometry methods for early detection of acute hematologic malignancies in Kenya. The key objectives are to: Validate and measure the concordance of flow cytometry tests comparing bone marrow aspiration and peripheral blood samples for leukemia diagnosis. This will assess the feasibility of using a less invasive...

This Project Grant award of $700,049 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund a study on the impact of targeted tyrosine kinase inhibitor (TKI) therapies on cancer-related cognitive impairment (CRCI) among patients with chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). The study, led by the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, will recruit 200 patients about to begin TKI treatment for CML or CLL,...

The National Cancer Institute (NCI) awarded a $647,458 Cooperative Agreement under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Massachusetts Institute of Technology (MIT) to develop a novel platform for real-time functional assessment of Acute Myeloid Leukemia (AML) minimal residual disease (MRD) therapeutic vulnerabilities. The project aims to integrate MIT's high-precision biophysical measurements, DeepCell's label-free brightfield imaging and AI-powered sorting,...

This $124,230 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research led by Dr. Parikh at the Mayo Clinic in Rochester, Minnesota. The key objectives are to: 1) Complete two ongoing clinical trials evaluating novel combination treatments for untreated chronic lymphocytic leukemia (CLL) patients, including data analysis and manuscript preparation; and 2) Develop the protocol and serve as the national principal investigator for...

This Project Grant award, titled "MULTIPLEX EPITOPE EDITING TO ENABLE NOVEL IMMUNOTHERAPIES FOR ACUTE MYELOID LEUKEMIA", is funded by the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program. The $2,282,666 award to The Children's Hospital Corporation, doing business as Boston Children's Hospital, aims to develop innovative immunotherapy approaches for acute myeloid leukemia (AML) by genetically engineering hematopoietic stem/progenitor cells to...

The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...

This Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to characterize the molecular phenotypes and therapeutic vulnerabilities of different leukemia-initiating cell (LIC) subpopulations in acute myeloid leukemia (AML). The $1,162,890 award, with a performance period from July 2024 to June 2029, will support research to develop more effective and durable therapies for AML, particularly for therapy-resistant subtypes such as those with...

This federal Project Grant award of $738,698 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will support research at the Beckman Research Institute of the City of Hope to develop a novel combination therapy for relapsed/refractory acute myelogenous leukemia (AML) in patients over 60 years old. The key objectives are to: 1) Establish the appropriate dosing of the anti-CD38 targeted alpha therapy (225Ac-DOTA-daratumumab) when combined with total marrow...

The National Cancer Institute awarded Syntrix Biosystems Inc. a $1,427,270 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to conduct a dose expansion study of SX-682, alone and in combination with decitabine, in patients with myelodysplastic syndromes (MDS). MDS are pre-leukemic disorders with limited treatment options, as only four drugs have been approved for MDS and current therapies have suboptimal response rates and durability. This 4-year project, beginning in...

The National Cancer Institute (NCI) awarded a $647,398 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Regents of the University of Michigan. The 5-year grant, awarded on December 1, 2024, aims to develop novel quantitative bone marrow magnetic resonance imaging (MRI) biomarkers to assess the efficacy of new molecularly targeted agents for the treatment of myelofibrosis, a fatal blood cancer. The research will focus on applying advanced MRI...